ENTITY
Antengene

Antengene (6996 HK)

55
Analysis
Health Care • China
Antengene is a global, R&D-driven, commercial-stage biotech company focused on discovering, developing, manufacturing, and commercializing first-in-class/best-in-class therapeutics for hematologic malignancies and solid tumors. Its pipeline includes in-house discovered programs like ATG-022 and ATG-101, and its lead commercial asset is XPOVIO® (selinexor). The company also developed the AnTenGager® T cell engager platform. Antengene is headquartered in Shanghai, China, and was founded in 2017.
more
bullish•Ant Group
•25 Oct 2020 11:14

ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...

Share
bullish•Antengene
•21 Oct 2020 10:37

Antengene (德琪医药) Pre-IPO: Proven R&D Track Record by Founder Matters

Antengene, a China-based biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex...

Logo
572 Views
Share
x